U.S. FDA Clears Mexico Site For Dr. Reddy’s As Company Nears Goal of $3 Billion In Sales
This article was originally published in PharmAsia News
Executive Summary
A slew of launches and growth in emerging markets will have to counter an increasingly tough U.S. market